<DOC>
	<DOCNO>NCT02529839</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy immunoablative nonmyeloablative conditioning protocol autologous bone marrow transplantation patient Multiple Sclerosis . Patients meet inclusion exclusion criterion start immunoablative nonmyeloablative conditioning regimen follow autologous bone marrow transplantation . Patients follow one year neurologist evaluate course disease treatment .</brief_summary>
	<brief_title>Safety Efficacy Immunoablative Nonmyeloablative Conditioning Protocol Autologous Bone Marrow Transplantation ( BMT ) Patients With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Consenting patient fulfil Poser 's clinical criterion definite MS 2 . Age : 1865 , male females 3 . Relapsing secondary progressive form MS evidence significant activity MS ( clinical MRI ) . 4 . EDSS score 2.0 7.0 ( see table 1 ) . 5 . Failure least one line currently available treatment , register treatment ( i.e . interferon , Copaxone , Tysabri , Gilenya , Tecfidera , immunosuppression ) MS . The lack response treatment determined/defined either increase ( deterioration ) one degree ( ) EDSS score , baseline EDSS le 5.0 0.5 degree , baseline EDSS 5.0 , last year appearance one major relapse MS period time ( treatment ) , evidence new activity MS ( new T2 lesion gadolinium enhance lesion ) last 12 month . 6 . Duration disease : &gt; 2 year , except case rapid progression , i.e . annual relapse rate â‰¥2 per 2 year conventional treatment malignant multiple sclerosis intense symptom ( types case deadly ) . 1 . Patients suffer significant cardiac , renal hepatic failure disease may risk patient interfere ability undergo high dose immunosuppression associate toxicity ( accord exist limitation autologous transplantation ) . 2 . Patients active infection . 3 . Patients severe cognitive decline inability understand sign inform consent . 4 . Patients treat investigational protocol last 3 month prior inclusion . 5 . Patients receive high dose immunosuppression autologous stem cell rescue past effect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MS</keyword>
	<keyword>BMT</keyword>
</DOC>